Quote:

---

CR
Biomarker was one of the first initiatives. By doing the biomarkers, that helps us be able to select which patients we think would respond. Part of that is also understanding the Mechanism of Action. And knowing all of that helps us better design clinical trials. So our upcoming long-haulers trial, we spent a lot of time into that, a lot of the development actually happened through the biomarker lab.

And what we’re seeing actually in NASH as well.

And we’re just started with the biomarkers, so I look forward to a lot of trials that we can actually accelerate faster by identifying those patients that we can help them better with, that have that predisposition.

---

This quote from Recknor (above) is why I said this last night: When the book is written, we are all going to find out the "mystery of the science." For some reason, LL doesn't work consistently enough in everyone. It requires a specialized trial design. No one has figured it out yet. When they do, it might be amazing.

(We may have it with Brazil, but too early to know.)